azacitidine has been researched along with Sarcoma in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, F; Bao, L; Chencheri, SC; Krishnadas, DK; Lucas, K | 1 |
| Bai, F; Cheerva, AC; Diller, L; George, RE; Krishnadas, DK; Lucas, KG; Shusterman, S; Sullivan, JE | 1 |
| Benhattar, J; Braunschweig, R; Coindre, JM; Guilleret, I; Guillou, L; Yan, P | 1 |
| Facchinetti, F; Mezzanzanica, D; Modena, P; Pilotti, S; Radice, MT; Sozzi, G; Testi, MA | 1 |
| Ayyoub, M; Hesdorffer, CS; Hesdorffer, M; Hibshoosh, H; Keohan, ML; Mansukhani, M; Memeo, L; Metthez, G; Taub, RN; Valmori, D | 1 |
| Ghoshal, K; Jacob, ST; Majumder, S | 1 |
1 trial(s) available for azacitidine and Sarcoma
| Article | Year |
|---|---|
A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma.
Topics: Adolescent; Antigens, Neoplasm; Azacitidine; Cancer Vaccines; Cell Proliferation; Cells, Cultured; Child; Child, Preschool; Combined Modality Therapy; Decitabine; Dendritic Cells; Feasibility Studies; Female; Humans; Male; Melanoma-Specific Antigens; Membrane Proteins; Neoplasm Proteins; Neuroblastoma; Peptide Fragments; Recurrence; Sarcoma; T-Lymphocytes; Treatment Outcome | 2015 |
5 other study(ies) available for azacitidine and Sarcoma
| Article | Year |
|---|---|
Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Decitabine; HLA Antigens; Humans; Intercellular Adhesion Molecule-1; Melanoma-Specific Antigens; Membrane Proteins; Neoplasm Proteins; Sarcoma; T-Lymphocytes, Cytotoxic; Up-Regulation | 2014 |
The human telomerase RNA gene (hTERC) is regulated during carcinogenesis but is not dependent on DNA methylation.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Division; Cell Line; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Neoplasms; Polymorphism, Genetic; Promoter Regions, Genetic; Protein Conformation; Reverse Transcriptase Polymerase Chain Reaction; RNA; Sarcoma; Sulfites; Telomerase; Tumor Cells, Cultured | 2002 |
UQCRH gene encoding mitochondrial Hinge protein is interrupted by a translocation in a soft-tissue sarcoma and epigenetically inactivated in some cancer cell lines.
Topics: Antineoplastic Agents; Azacitidine; Base Sequence; Breast Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 22; CpG Islands; DNA Methylation; DNA-Binding Proteins; Electron Transport Complex III; Exons; Extrachromosomal Inheritance; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Kruppel-Like Transcription Factors; Molecular Sequence Data; Neoplasm Proteins; Ovarian Neoplasms; Promoter Regions, Genetic; Proteins; Repressor Proteins; RNA-Binding Protein EWS; Sarcoma; Soft Tissue Neoplasms; Translocation, Genetic; Tumor Cells, Cultured | 2003 |
The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma.
Topics: Antibodies, Neoplasm; Antigens, Neoplasm; Autoantigens; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; HLA-A2 Antigen; Humans; Immunohistochemistry; Immunotherapy; Interferon-gamma; Membrane Proteins; Neoplasm Proteins; Polymerase Chain Reaction; Sarcoma | 2004 |
Analysis of promoter methylation and its role in silencing metallothionein I gene expression in tumor cells.
Topics: Animals; Azacitidine; Base Sequence; CpG Islands; DNA Methylation; Gene Expression Regulation, Neoplastic; Gene Silencing; Liver Neoplasms, Experimental; Metallothionein; Metals; Mice; Molecular Sequence Data; Polymerase Chain Reaction; Promoter Regions, Genetic; RNA, Messenger; Sarcoma; Sulfites; Tumor Cells, Cultured | 2002 |